T1D Prediction ProgrammeBasic Info
What is T1D Prediction Programme?
Type 1 diabetes (T1D) is the result of an autoimmune destruction of pancreatic beta cells based on complex interactions among genetic predisposition and enviromentral factors.
The Czech Republic has an intermediate T1D incidence (18.3/100 000 children/year in 2003) compared to other European countries but continous rise mainly in the preschool age category is expected.
Since 2001 “T1D prediction programme” has been available for the first degree relatives of T1D patients in the Czech Republic who are under 18 years of age. The programme currently comprises 1148 children (598 boys).
The Prediction Programme includes:
1) HLA genotyping
Life long risk for diabetes.
2) Assesing of GAD65, IA2 and IAA autoantibodies.
On annual or biannual basis according to HLA genotype.
3) Intravenous glucose tolerance testing
To asses the first phase insulin response in children who are autoantibodies positive.
4)ZnT8A autoantibodies
They will be added in june to improve the stratification of T1D risk.
5)The evaluation of peripheral blood mononuclear cells cytokine profile
To understand better the immunological profile of programme participants, we examined the response of their immunocompetent cells to diabetes associated autoantigens by using Elisa array and gene microarrays (Phalanx or NimbleGen platform).
Comparison of cellular imunity and autoantibodies help us to better understand the autoimmunity process during each period of incipient diabetes. It can help us also to find new cellular marker for early stage of diabetes.
Only complex immunogenetic analysis can help us to reveal the person who is in the real risk of speedy T1D onset and who is the ideal object for the application of immunointervention.
Contacts:
Information email address for patients info@predia.cz
Personal contacts:
• Stanislava Koloušková MD, Programme leader of clinical part
• Stanislava Koloušková MD, Programme leader of clinical part
• Assoc. prof.Kateřina Štechová MD, PhD. , Head of the laboratory part
• M.Sc. Jana Včeláková (Šiftancová), laboratory part and autoantibodies detection
• Lenka Petruželková MD, clinical part and autoantibodie detection
• Michaela Vyhnálková, Nurse
The programme is supported by projects 00064203 (Czech Ministry of Health) and NPVII 2B06019 (Czech Ministry of Education).